4 unknown, 1 active not recruiting, 1 not yet recruiting, 1 suspended. 4 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Unknown 2, Not yet recruiting 1, Suspended 1 |
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow CM082: new trials by email Literature Review of CM082 trials Research Report on CM082
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma Vorolanib Tablets, Vorolanib + Toripalimab - Renal Cell Carcinoma (RCC), Adjuvant | Phase 2 | Active not recruiting | Dong Wen | 60 | 2025-04-24 | 2025-07-09 |
| Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients Vorolanib, cadonilimab - Kidney Cancer, RCC | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 37 | 2024-08-31 | 2024-08-29 |
| CM082 in Patients With Myopic Choroidal Neovascularization (CNV) CM082 - Myopic Choroidal Neovascularisation | Phase 1 | Suspended | AnewPharma | 96 | 2019-12-18 | 2021-03-10 |
| Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors CM082 - Advanced Malignant Solid Tumors | Phase 1 | Unknown | AnewPharma | 19 | 2019-02-26 | 2022-11-14 |
| Safety and Tolerability of Oral CM082 in Patients With wAMD CM082 - Age-Related Macular Degeneration | Phase 2 | Unknown | AnewPharma | 64 | 2018-11-22 | 2020-01-13 |
| CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma CM082 combined with everolimus, CM082, Everolimus - Renal Cell Cancer Metastatic | Phase 3 | Unknown | AnewPharma | 390 | 2016-12-16 | 2021-02-08 |
| Study of the Combination of CM082 With Everolimus in Patients With mRCC CM082, Everolimus - Renal Cell Carcinoma Recurrent | Phase 1 | Unknown | AnewPharma | 18 | 2015-09-01 | 2018-01-10 |
Carcinoma, Renal Cell (2) · Kidney Neoplasms (1) · Macular Degeneration (1)
AnewPharma (5) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Dong Wen (1)
China (6)
Jin Li, M.D (1) · Jun Guo, M.D (1) · Jun Guo, MD (1) · Xinan Sheng, M.D (1) · Yin Shen (1) · Youxin Chen (1)